Literature DB >> 12233897

Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort.

Kiem Oen1, Peter N Malleson, David A Cabral, Alan M Rosenberg, Ross E Petty, Mary Cheang.   

Abstract

OBJECTIVE: To determine the disease course and outcome in a multicenter cohort of patients with juvenile rheumatoid arthritis (JRA).
METHODS: All patients with JRA seen at 3 pediatric rheumatology centers were identified from databases and/or clinic records. Inclusion criteria were a diagnosis of JRA (1977 American College of Rheumatology criteria), a followup period of at least 5 years since onset, and a minimum age of 8 years. Patients were examined and completed a Childhood Health Assessment Questionnaire (CHAQ). Kaplan-Meier curves were constructed to estimate rates of remission, relapse, and arthroplasty. Remission was defined as absence of active arthritis while off treatment for at least 2 years. Outcome measures were active disease duration, CHAQ scores, pain determined by visual analog scales, physician's global assessments, and Steinbrocker functional classifications. Years of education and employment status were ascertained.
RESULTS: We studied 392 patients of 652 (60%) who met the selection criteria. The probabilities of remission at 10 years after onset were 37, 47, 23, and 6% for patients with systemic, pauciarticular, RF- polyarticular, and RF+ polyarticular JRA, respectively. The probability of relapse varied from 30 to 100% at 15 years. The probability of arthroplasty varied from 13 to 57% after 15 years of active disease. We found 2.5% of patients assessed were in Steinbrocker Classes III or IV and 6% were in the highest CHAQ score (> 1.5) group. Compared with national statistics, fewer female patients received post-secondary education and unemployment rates for patients 20 to 24 years of age were higher.
CONCLUSION: Our results indicate that JRA is a disease that often extends into adulthood. Compared to previous decades, functional outcome has improved; however, the estimated rate of arthroplasty remains very high. Patients with JRA may have difficulty entering the workforce.

Entities:  

Mesh:

Year:  2002        PMID: 12233897

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  62 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Course of juvenile rheumatoid arthritis: social life is less affected than school functioning, physical activity, and well-being during a follow-up of 1.5-13 years.

Authors:  V Terrones-Munoz; C Mélot; V Gangji; S Steinfeld; Th Appelboom
Journal:  Eur J Pediatr       Date:  2006-04-07       Impact factor: 3.183

Review 3.  Transition of care from paediatric to adult rheumatology.

Authors:  Janet E McDonagh
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

4.  Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis.

Authors:  Peter Marti; Luciano Molinari; Isabel B Bolt; Reinhard Seger; Rotraud K Saurenmann
Journal:  Eur J Pediatr       Date:  2007-06-12       Impact factor: 3.183

5.  Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment.

Authors:  Rabina Kochar; Kyle M Walsh; Anil Jain; Steven J Spalding; Philip J Hashkes
Journal:  Rheumatol Int       Date:  2011-09-11       Impact factor: 2.631

6.  Validation of administrative case ascertainment algorithms for chronic childhood arthritis in Manitoba, Canada.

Authors:  Natalie Jane Shiff; Kiem Oen; Rasheda Rabbani; Lisa M Lix
Journal:  Rheumatol Int       Date:  2017-05-13       Impact factor: 2.631

7.  Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects.

Authors:  Megan L Krause; Jorge A Zamora-Legoff; Cynthia S Crowson; Theresa Wampler Muskardin; Thomas Mason; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2016-07-18       Impact factor: 5.532

8.  [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].

Authors:  K Minden; J Klotsche; M Niewerth; G Horneff; A Zink
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

9.  The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center.

Authors:  Aimee O Hersh; Shirley Pang; Megan L Curran; Diana S Milojevic; Emily von Scheven
Journal:  Pediatr Rheumatol Online J       Date:  2009-06-08       Impact factor: 3.054

10.  Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study.

Authors:  Kimme L Hyrich; Sham D Lal; Helen E Foster; Judith Thornton; Navid Adib; Eileen Baildam; Janet Gardner-Medwin; Lucy R Wedderburn; Alice Chieng; Joyce Davidson; Wendy Thomson
Journal:  Rheumatology (Oxford)       Date:  2009-11-19       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.